poisar

Stocks · News reference

Wegovy for Overweight Young Children: Novo Nordisk’s Obesity Drug Shows Effectiveness

Vandana Singh

Novo Nordisk Phase 3 STEP Young trial shows once-weekly semaglutide reduced BMI in 40.4% of children with obesity after 68 weeks.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NVO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Reuben Gregg Brewer

    Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

    Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.

    NVOLLY
  2. Na

    Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

    Novo Nordisk announced positive phase III STEP Young study results showing semaglutide reduced BMI in children aged 6-12 with obesity, with 40.4% no longer classified as obese after 68 weeks. However, the company faces mounting competitive pressure from Eli Lilly's superior weight-loss drugs and emerging biotech competitors in the GLP-1 obesity treatment market.

    NVOLLYVKTXGPCR
  3. Reuben Gregg Brewer

    Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

    Eli Lilly's GLP-1 weight-loss drugs (Mounjaro, Zepbound) currently drive nearly two-thirds of revenue, but face competition and patent expiration risks. The company is strategically acquiring smaller biotech firms across autoimmune, mental health, sleep disorders, and infectious disease spaces to diversify its pipeline and prepare for when GLP-1 drugs are no longer its primary revenue driver.

    LLYNVOPFE